Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HRP004
MIFTS: 60

Herpes Zoster

Categories: Infectious diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Herpes Zoster

About this section

MalaCards integrated aliases for Herpes Zoster:

Name: Herpes Zoster 12 73 43 53 54 44 15 17
Shingles 12 73 43 53 42 3 62
Herpes Zoster Disease 70
Herpes Zona 12
Zoster 43

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8536
ICD9CM 34 053
MeSH 44 D006562
NCIt 50 C71079
SNOMED-CT 67 186514003
UMLS 70 C0019360
Sources

Summaries for Herpes Zoster

About this section
MedlinePlus : 42 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What other problems can shingles cause? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary : Herpes Zoster, also known as shingles, is related to postherpetic neuralgia and chickenpox, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is FCGR3A (Fc Fragment Of IgG Receptor IIIa), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Foscarnet and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include nerve fiber, skin and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

MedlinePlus Genetics : 43 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50.Shingles is characterized by a severely painful, itchy, or tingling rash, most commonly on one side of the torso, although it can occur anywhere on the body. Reactivation of the virus usually occurs in a single nerve, leading to the symptoms of shingles in just the region of skin connected to that nerve. When the nerve connected to the eye and the skin surrounding it is affected, the condition is called herpes zoster ophthalmicus. This form of shingles, which accounts for about 20 percent of cases, can cause permanent vision impairment.Some individuals with shingles feel throbbing or tingling in the affected region shortly before the rash appears. Blisters form in the rash area, break open, and scab over in a few days. Healing usually takes 2 to 4 weeks. Most people have only one episode of shingles, although it can recur in rare cases.In 5 to 20 percent of people with shingles, severe pain continues in the affected region after healing of the rash, which is known as postherpetic neuralgia (PHN). PHN is the most common complication of shingles. It can also involve severe itchiness or an overactive pain response to things that do not usually cause pain (allodynia), such as a light touch. PHN can last weeks, months, or even years. The likelihood of developing PHN after shingles and its severity increase with age. The pain caused by shingles and PHN can disrupt day-to-day activities and reduce a person's quality of life.

CDC : 3 Shingles is a painful rash that usually develops on one side of the body, often the face or torso. The rash consists of blisters that typically scab over in 7 to 10 days and clears up within 2 to 4 weeks. Some people describe the pain as an intense burning sensation. For some people, the pain can last for months or even years after the rash goes away. This long-lasting pain is called postherpetic neuralgia (PHN), and it is the most common complication of shingles. Your risk of getting shingles and PHN increases as you get older. Two vaccines are licensed and recommended to prevent shingles in the U.S.. Zoster vaccine live (ZVL, Zostavax) has been in use since 2006. Recombinant zoster vaccine (RZV, Shingrix), has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine

NINDS : 53 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 62 About shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body. People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox. Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications. Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

Wikipedia : 73 Shingles, also known as zoster or herpes zoster, is a viral disease characterized by a painful skin rash... more...

Sources

Related Diseases for Herpes Zoster

About this section

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1177)
# Related Disease Score Top Affiliating Genes
1 postherpetic neuralgia 33.0 HLA-DRB1 HLA-B HLA-A
2 chickenpox 31.9 IL2 IL10 IFNG IFNA1 GYPC FCGR3A
3 exanthem 31.8 PDCD1 IL2 IL10 IFNG IFNA1 CD8A
4 encephalitis 31.6 TLR3 TLR2 IL10 CCR5
5 neuritis 31.6 IL10 IFNG HLA-DRB1 CCR5
6 keratitis, hereditary 31.4 TLR2 IL10 CD8A
7 optic neuritis 31.3 IL10 HLA-DRB1 HLA-A CCR5
8 iritis 31.2 IL10 HLA-B CD8A
9 herpes simplex 31.2 TLR3 TLR2 IFNA1 GYPC
10 meningitis 31.2 TLR2 IL2 IL10 IFNG HLA-B
11 uveitis 31.2 IL2 IL10 IFNG IFNA2 HLA-B HLA-A
12 lupus erythematosus 31.1 PDCD1 IL10 IFNG HLA-DRB1 FCGR3A
13 myositis 31.1 IL2 IFNG IFNA1 HLA-DRB1 HLA-B
14 spondylitis 31.1 IL10 IFNG HLA-B
15 ulcerative colitis 30.9 IL2 IL10 IFNG HLA-DRB1
16 pemphigus 30.9 IL10 HLA-DRB1 COL17A1
17 conjunctivitis 30.9 TLR3 IL2 IL10 IFNG HLA-B
18 pemphigoid 30.9 IFNG HLA-DRB1 COL17A1
19 arthritis 30.9 TRPV1 TLR2 IL10 IFNG HLA-DRB1 HLA-B
20 temporal arteritis 30.8 IL2 IFNG HLA-DRB1 CD8A
21 genital herpes 30.8 TLR2 IL10 GYPC CD8A
22 pityriasis rosea 30.8 HLA-DRB1 HLA-B HLA-A
23 fasciitis 30.8 IL2 IFNG IFNA1
24 dermatitis 30.8 TLR2 IL2 IL10 IFNG CD8A
25 chronic graft versus host disease 30.8 IL10 IFNG CCR5
26 allergic disease 30.8 TLR2 IL2 IL10 IFNG
27 lichen planus 30.8 IL2 IL10 IFNG COL17A1
28 syphilis 30.7 IFNG HLA-DRB1 CD8A CCR5
29 graft-versus-host disease 30.7 IL2 IL10 IFNG HLA-DRB1 HLA-B HLA-A
30 cutaneous lupus erythematosus 30.7 IL10 IFNG IFNA1
31 sarcoidosis 1 30.7 IL2 IFNG HLA-DRB1 HLA-A CD8A CCR5
32 leukemia, chronic lymphocytic 30.7 IL2 IL10 IFNA1 FCGR3A CD8A CCR5
33 vaccinia 30.7 IL2 IFNA1 HLA-B CCR5
34 mumps 30.7 TLR3 IL2 IL10 IFNG IFNA1 HLA-DRB1
35 osteomyelitis 30.7 TLR2 IL10 IFNG
36 psoriasis 30.7 TLR2 IL2 IL10 IFNG HLA-DRB1 HLA-B
37 contact dermatitis 30.7 TLR2 IL2 IL10 IFNG
38 mycosis fungoides 30.6 IL2 IFNG IFNA2 IFNA1
39 psoriatic arthritis 30.6 TLR2 IL2 IL10 IFNG HLA-DRB1 HLA-B
40 kaposi sarcoma 30.6 IFNA2 IFNA1 HLA-B HLA-A CCR5
41 skin disease 30.6 TLR2 IL2 IL10 IFNG IFNA1 HLA-B
42 rubella 30.6 TLR3 IL2 IL10 IFNG HLA-DRB1 HLA-B
43 discoid lupus erythematosus 30.6 IL10 IFNA2 IFNA1 HLA-DRB1
44 pneumonia 30.6 TLR3 TLR2 IL10 IFNG
45 disease by infectious agent 30.6 TLR2 IL2 IL10 IFNG IFNA1 CD8A
46 pulmonary tuberculosis 30.6 TLR2 IL2 IL10 IFNG HLA-DRB1
47 human immunodeficiency virus type 1 30.5 TLR3 IL2 IL10 IFNG HLA-B HLA-A
48 pulmonary disease, chronic obstructive 30.5 TRPV1 TLR2 IL10 CD8A CCR5
49 viral encephalitis 30.5 TLR3 IL10 IFNA1 CD8A
50 chorioretinitis 30.5 IL2 IL10 IFNG CD8A

Graphical network of the top 20 diseases related to Herpes Zoster:



Diseases related to Herpes Zoster
Sources

Symptoms & Phenotypes for Herpes Zoster

About this section

Symptoms:

12
  • • fever
  • • paresthesia
  • • headache
  • • malaise
  • • itching
  • • rash which is followed by blisters
  • • burning pain

UMLS symptoms related to Herpes Zoster:


seizures; tremor; fever; back pain; angina pectoris; headache; pruritus; syncope; pain; chronic pain; sciatica; exanthema; vertigo/dizziness; equilibration disorder; sleeplessness

GenomeRNAi Phenotypes related to Herpes Zoster according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.72 HLA-A HLA-B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.72 HLA-A HLA-B
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 9.72 IFNA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.72 IFNA1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.72 HLA-A HLA-B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.72 HLA-A HLA-B IFNA1 IFNA2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.72 HLA-A HLA-B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.72 IFNA1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.72 IFNA2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.72 IFNA1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.72 HLA-A HLA-B
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.72 IFNA1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.72 IFNA1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.72 HLA-A HLA-B
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.72 IFNA1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-88 9.72 IFNA1

MGI Mouse Phenotypes related to Herpes Zoster:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCR5 CD8A DHFR DPYD GYPC HLA-A
2 immune system MP:0005387 9.93 CCR5 CD8A DHFR DPYD HLA-A IFNG
3 liver/biliary system MP:0005370 9.56 CCR5 DHFR IFNG IL10 IL2 PDCD1
4 neoplasm MP:0002006 9.23 CCR5 IFNG IL10 IL2 PDCD1 TLR2
Sources

Drugs & Therapeutics for Herpes Zoster

About this section

PubMed Health treatment related to Herpes Zoster: 62

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin ). Prescription painkillers are sometimes used to relieve more severe pain. Thorough skin care is recommended if you have shingles . Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters . Most of them contain tanins, zinc , menthol or polidocanol . If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work. Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system , if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy ." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion ). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
2
Budesonide Approved Phase 4 51333-22-3 63006 5281004
3
Ethanol Approved Phase 4 64-17-5 702
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Acyclovir Approved Phase 4 59277-89-3 2022
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
8
Vedolizumab Approved Phase 4 943609-66-3
9
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
10
Certolizumab pegol Approved Phase 4 428863-50-7
11
Infliximab Approved Phase 4 170277-31-3
12
Mercaptopurine Approved Phase 4 50-44-2 667490
13
Azathioprine Approved Phase 4 446-86-6 2265
14
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Tofacitinib Approved, Investigational Phase 4 477600-75-2
17
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
18 Reverse Transcriptase Inhibitors Phase 4
19 Psychotropic Drugs Phase 4
20 Excitatory Amino Acid Antagonists Phase 4
21 Anticonvulsants Phase 4
22 Anti-Anxiety Agents Phase 4
23 calcium channel blockers Phase 4
24 Hormones Phase 4
25 Calcium, Dietary Phase 4
26 Respiratory System Agents Phase 4
27 Hormone Antagonists Phase 4
28 Anti-Asthmatic Agents Phase 4
29 glucocorticoids Phase 4
30 Bronchodilator Agents Phase 4
31 Anti-Inflammatory Agents Phase 4
32 polysaccharide-K Phase 4
33 Mesalamine Phase 4 89-57-6
34 Janus Kinase Inhibitors Phase 4
35 Immunologic Factors Phase 4
36 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
37 Immunosuppressive Agents Phase 4
38
Calcium Nutraceutical Phase 4 7440-70-2 271
39
Methylene blue Approved, Investigational Phase 3 61-73-4
40
Famciclovir Approved, Investigational Phase 3 104227-87-4 3324
41
Morphine Approved, Investigational Phase 3 57-27-2 5288826
42
carbamide peroxide Approved Phase 3 124-43-6
43
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
44
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934
45
Methadone Approved Phase 3 76-99-3 4095
46
Desipramine Approved, Investigational Phase 3 50-47-5 2995
47
Nortriptyline Approved Phase 3 72-69-5 4543
48
Altretamine Approved Phase 3 645-05-6 2123
49
Sorivudine Investigational Phase 3 77181-69-2
50 Anti-Infective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 278)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya. Unknown status NCT02514018 Phase 4
2 A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Unknown status NCT02444936 Phase 4 ZOSTAVAX
3 A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
4 Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations Unknown status NCT00940940 Phase 4
5 Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
6 Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
7 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
8 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
9 Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia Completed NCT00885586 Phase 4 gabapentine
10 Immune Response to Shingles Vaccination Completed NCT02624375 Phase 4 Zoster Vaccine Live
11 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
12 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
13 A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age Completed NCT00550745 Phase 4
14 T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape Completed NCT01911065 Phase 4
15 An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea Completed NCT01556451 Phase 4
16 An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old. Completed NCT00681031 Phase 4
17 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
18 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia and for the Prevention of Post Herpetic Neuralgia- a Randomized Controlled Trial Completed NCT03809702 Phase 4 Pregabalin;Placebo
19 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
20 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
21 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
22 Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina Completed NCT00830648 Phase 4
23 Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
24 A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
25 Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
26 Live Attenuated Varicella Vaccine: A New Effective Adjuvant Weapon in the Battlefield Against Severe Resistant Psoriasis, a Randomized Controlled Trial Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
27 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study) Recruiting NCT02868970 Phase 4
28 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
29 The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting NCT03591770 Phase 4
30 Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
31 The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER) Recruiting NCT03886038 Phase 4
32 Ultrasound Guided Erector Spinae Block Versus Ultrasound Guided Thoracic Paravertebral Block for Pain Relief in Patients With Acute Thoracic Herpes Zoster Recruiting NCT04656821 Phase 4 Control Rx
33 Safety and Immunogenicity of Recombinant Glycoprotein E Herpes Zoster Subunit (HZ/su) Vaccine in Renal Transplant Recipients Recruiting NCT03993717 Phase 4
34 Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation Active, not recruiting NCT03016884 Phase 4
35 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Active, not recruiting NCT03493776 Phase 4
36 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Active, not recruiting NCT03330171 Phase 4
37 VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination Not yet recruiting NCT04403139 Phase 4 Shingrix
38 Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial Not yet recruiting NCT04748939 Phase 4
39 A Cross-over, Open-label, Single-group Study to Evaluate the Safety and Immunogenicity of Live Attenuated Varicella Vaccine Skyvaricella Injection (Inj.) Developed by SK Bioscience (Company Limited) Co., Ltd of South Korea in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old Not yet recruiting NCT04384016 Phase 4
40 A Double Blind Placebo-controlled Randomized Study of Varicella Zoster Vaccine in Patients With Moderate-to-severe Plaque Psoriasis Who Are Candidates for Biologic Therapy Terminated NCT02408159 Phase 4 Varicella Zoster Vaccine;Placebo
41 Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine Withdrawn NCT02026089 Phase 4
42 A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections Unknown status NCT03178747 Phase 3
43 Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation Unknown status NCT00213304 Phase 3
44 Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery Unknown status NCT00926419 Phase 2, Phase 3
45 A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00300222 Phase 3 NGX-4010
46 A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00115310 Phase 3 NGX-4010
47 Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Completed NCT00098046 Phase 3 famciclovir
48 Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster Completed NCT01827839 Phase 3
49 A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age Completed NCT00534248 Phase 3
50 Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies Completed NCT02690207 Phase 3

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acyclovir
Acyclovir Sodium
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
famciclovir
Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
valacyclovir
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes zoster

Sources

Genetic Tests for Herpes Zoster

About this section
Sources

Anatomical Context for Herpes Zoster

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Zoster:

19
Nerve Fiber

MalaCards organs/tissues related to Herpes Zoster:

40
Skin, Eye, Bone Marrow, T Cells, Spinal Cord, Bone, Myeloid
Sources

Publications for Herpes Zoster

About this section

Articles related to Herpes Zoster:

(show top 50) (show all 10259)
# Title Authors PMID Year
1
Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years of age: an observational study using active surveillance. 61 42
33766842 2021
2
Should we prescribe anticonvulsants for acute herpes zoster neuralgia and to prevent postherpetic neuralgia?: A protocol for meta-analysis and benefit-risk assessment. 42 61
33607769 2021
3
Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients. 42 61
33499826 2021
4
Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. 54 61
14593495 2005
5
Chronic varicella-zoster virus skin lesions in patients with human immunodeficiency virus are related to decreased expression of gE and gB. 61 54
9207378 1997
6
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. 61 54
9164418 1997
7
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 54 61
1569421 1992
8
[Therapeutic indications in herpes zoster]. 61 54
1828198 1991
9
Detection of SARS-CoV-2 RNA in the corneal epithelium of a patient after recovery from COVID-19. 61
33748538 2021
10
Successful treatment with famciclovir for varicella zoster virus infection resistant to acyclovir. 61
33358593 2021
11
Disseminated Varicella-zoster Virus Infection Causing Fatal Pneumonia in an Immunocompromised Patient with Chronic Interstitial Pneumonia. 61
33162474 2021
12
Genus Lilium: A review on traditional uses, phytochemistry and pharmacology. 61
33485985 2021
13
Use of Selected Recommended Clinical Preventive Services - Behavioral Risk Factor Surveillance System, United States, 2018. 61
33793461 2021
14
Multiple dermatomal granulomatous dermatitis concurring with herpes zoster. 61
33580911 2021
15
[Skin diseases as indicators of cancer]. 61
33730256 2021
16
A Case of Eosinophilic Pustular Folliculitis Associated With Herpes Zoster. 61
33156024 2021
17
The impacts of ambient temperature and ultraviolet radiation on the incidence of herpes zoster: An ecological study in Taiwan. 61
33237617 2021
18
Serum interleukin-10 level increases in patients with severe signs or symptoms of herpes zoster and predicts the duration of neuralgia. 61
33609414 2021
19
Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects. 61
32810347 2021
20
Outpatient healthcare utilization and prescribing patterns for herpes zoster in United States adults. 61
32390077 2021
21
Risk of severe herpes zoster infection in patients with polycystic kidney disease: A nation-wide cohort study with propensity score matching analysis. 61
32798268 2021
22
Oral lesions of herpes zoster in COVID-19 patients or truly associated to the disease? 61
32524663 2021
23
Intravenous patient-controlled analgesia hydromorphone combined with pregabalin for the treatment of postherpetic neuralgia: a multicenter, randomized controlled study. 61
33785673 2021
24
Bilateral Scalp Necrosis in Giant Cell Arteritis. 61
31633591 2021
25
AAAPT Diagnostic Criteria for Acute Neuropathic Pain. 61
33575803 2021
26
Expanding frontiers in telehealth: video assisted at-home application of capsaicin 8% patch. 61
33759272 2021
27
Varicella-Zoster Virus Infection of Neurons Derived from Neural Stem Cells. 61
33804210 2021
28
Natural and Synthetic Saponins as Vaccine Adjuvants. 61
33807582 2021
29
Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. 61
33197294 2021
30
Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries. 61
33618947 2021
31
Exploring the seasonal drivers of varicella zoster transmission and reactivation. 61
33733653 2021
32
Herpes zoster in an immunocompetent host with C6 dermatitis and abducens nerve palsy. 61
33775592 2021
33
Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice. 61
33805880 2021
34
Protective role of natural killer cells in neuropathic pain conditions. 61
33769361 2021
35
Egg case concentrate of Mantis religiosa abrogates the accumulation of cadmium in muscular and bone tissues of African catfish via activation of nitric oxide and myeloperoxidase activity. 61
32510650 2021
36
[Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area]. 61
33762495 2021
37
Bilateral myelin oligodendrocyte glycoprotein-related optic neuritis presenting after herpes zoster subunit vaccination. 61
33775591 2021
38
Distinguishing Features of Anterior Uveitis Caused by Herpes Simplex Virus, Varicella-Zoster Virus and Cytomegalovirus. 61
33773985 2021
39
Incidence of varicella and herpes zoster after inclusion of varicella vaccine in national immunization schedule in Turkey: time trend study. 61
32703071 2021
40
Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review. 61
33551300 2021
41
Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines. 61
33762414 2021
42
Effectiveness of CT-guided epidural infiltration of steroids and local anesthetics for acute and chronic herpes zoster neuralgia. 61
33785313 2021
43
Mistaken identities: penile herpes zoster. 61
33727338 2021
44
Radiotherapy combined with chemotherapy increases the risk of herpes zoster in patients with gynecological cancers: a nationwide cohort study. 61
33300312 2021
45
Increased risk of herpes zoster in gynecological cancer patients receiving radiotherapy combined with chemotherapy: a need for paying attention to vaccines. 61
33559416 2021
46
Hemorrhagic herpes zoster with contralateral multidermatomal distribution associated with rivaroxaban: An unusual presentation. 61
33604441 2021
47
Herpes zoster preferentially affected hair follicles involved in an acquired melanocytic nevus. 61
33768578 2021
48
Cigarette smoking and risk of herpes zoster: A population-based cohort study in Taiwan. 61
33763912 2021
49
Herpes zoster reactivation during head and neck cancer therapy: interpreting post-treatment positron emission tomography/CT imaging. 61
33692039 2021
50
A systematic literature review of herpes zoster incidence worldwide. 61
33651654 2021
Sources

Variations for Herpes Zoster

About this section
Sources

Expression for Herpes Zoster

About this section
Search GEO for disease gene expression data for Herpes Zoster.
Sources

Pathways for Herpes Zoster

About this section

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.99 TLR3 TLR2 PDCD1 IL2 IL10 IFNG
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.36 IL2 IL10 IFNG IFNA2 IFNA1 HLA-DRB1
3
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.2 TLR3 TLR2 IL2 IL10 IFNG IFNA2
4
PI3K-Akt signaling pathway 36
Show member pathways
 13 TLR3 TLR2 IL2 IFNA2 IFNA1 HLA-B
5
Human cytomegalovirus infection 36
Show member pathways
 12.95 TLR3 TLR2 IFNA2 IFNA1 HLA-B HLA-A
6
Herpes simplex virus 1 infection 36
12.7 TLR3 TLR2 IFNG IFNA2 IFNA1 HLA-DRB1
7
Th17 cell differentiation 36
Show member pathways
 12.59 TLR2 IL2 IL10 IFNG HLA-DRB1
8
T cell receptor signaling pathway 36
Show member pathways
 12.58 TLR2 PDCD1 IL2 IL10 IFNG CD8A
9
Interferon gamma signaling 65
Show member pathways
 12.54 IFNG IFNA2 IFNA1 HLA-DRB1 HLA-B HLA-A
10
Measles 36
Show member pathways
 12.52 TLR3 TLR2 IL2 IFNG IFNA2 IFNA1
11
JAK-STAT signaling pathway 36
Show member pathways
 12.42 IL2 IL10 IFNG IFNA2 IFNA1
12
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.39 IL2 IFNG IFNA2 IFNA1 HLA-B HLA-A
13
NF-kappaB Signaling 4
12.37 TLR3 TLR2 PDCD1 IL2 IL10 IFNG
14
Allograft rejection 1 36
Show member pathways
 12.35 IL2 IL10 IFNG IFNA2 IFNA1 HLA-DRB1
15
Human T-cell leukemia virus 1 infection 36
12.31 IL2 HLA-DRB1 HLA-B HLA-A
16
Toxoplasmosis 36
Show member pathways
 12.26 TLR2 IL10 IFNG HLA-DRB1 FCGR3A CCR5
17
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.23 IL2 IL10 IFNG IFNA2 IFNA1 HLA-B
18
Necroptosis 36
Show member pathways
 12.2 TLR3 IFNG IFNA2 IFNA1
19
Phagosome 36
12.16 TLR2 HLA-DRB1 HLA-B HLA-A FCGR3A
20
Cell adhesion molecules 36
12.14 PDCD1 HLA-DRB1 HLA-B HLA-A CD8A
21
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
12.09 HLA-B HLA-A FCGR3A CD8A
22
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12 IL2 IL10 IFNG IFNA2 CD8A
23
IL12-mediated signaling events 1
Show member pathways
 11.85 IL2 IFNG HLA-DRB1 HLA-A CD8A CCR5
24
Staphylococcus aureus infection 36
11.84 IL10 HLA-DRB1 FCGR3A
25
Rheumatoid arthritis 36
11.83 TLR2 IFNG HLA-DRB1
26
Innate Lymphoid Cell Differentiation Pathways 64
11.82 IL2 IL10 IFNG CD8A
27
Th17 Differentiation Pathway 64
Show member pathways
 11.81 TLR3 TLR2 IFNG
28
Interferon Pathway 63
11.81 IFNG IFNA2 IFNA1
29
Th1 Differentiation Pathway 64
Show member pathways
 11.74 TLR3 TLR2 IL2 IL10 IFNG
30
IgA-Producing B Cells in the Intestine 64
11.73 TLR2 PDCD1 IL10 FCGR3A
31
Dendritic Cells Developmental Lineage Pathway 64
11.7 IL2 IL10 IFNG IFNA2 CD8A
32
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.68 IL2 IFNG HLA-A CD8A
33
Malaria 36
11.56 TLR2 IL10 IFNG GYPC
34
Th2 Differentiation Pathway 64
11.5 IL2 IL10 IFNG
35
Tuberculosis 36
11.42 TLR2 IL10 IFNG IFNA2 IFNA1 HLA-DRB1
36
Type II interferon signaling (IFNG) 1
11.39 IFNG IFNA2 HLA-B
37
IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.38 IL2 IL10 IFNG
38
T-Cell Receptor and Co-stimulatory Signaling 1
11.31 PDCD1 IL2 CD8A
39
Cytokines and Inflammatory Response 1
11.29 IL2 IL10 IFNG HLA-DRB1
40
IL12 signaling mediated by STAT4 1
11.26 IL2 IFNG HLA-DRB1
41
OX40 Pathway 63
11.22 IL2 IL10 IFNG
Sources

GO Terms for Herpes Zoster

About this section

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.03 TLR3 IL2 IL10 IFNG IFNA2 IFNA1
2 cell surface GO:0009986 9.73 TLR3 TLR2 HLA-DRB1 HLA-B HLA-A CCR5
3 phagocytic vesicle membrane GO:0030670 9.54 TLR2 HLA-B HLA-A
4 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DRB1 HLA-B HLA-A
5 external side of plasma membrane GO:0009897 9.43 TRPV1 PDCD1 HLA-DRB1 FCGR3A CD8A CCR5
6 MHC class I protein complex GO:0042612 9.4 HLA-B HLA-A
7 integral component of plasma membrane GO:0005887 9.36 TRPV1 TLR3 TLR2 HLA-DRB1 HLA-B HLA-A
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-DRB1 HLA-B HLA-A

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.02 TRPV1 TLR3 TLR2 IFNA2 CCR5
2 immune system process GO:0002376 9.97 TLR3 TLR2 PDCD1 IL2 HLA-DRB1 HLA-B
3 cytokine-mediated signaling pathway GO:0019221 9.96 IL2 IL10 IFNA2 IFNA1 CCR5
4 defense response to virus GO:0051607 9.93 TLR3 IFNG IFNA2 IFNA1
5 defense response GO:0006952 9.91 TLR3 IFNA2 IFNA1 HLA-B
6 cell surface receptor signaling pathway GO:0007166 9.88 TRPV1 IFNG IFNA2 FCGR3A CD8A CCR5
7 positive regulation of interleukin-6 production GO:0032755 9.85 TLR3 TLR2 IFNG
8 positive regulation of tumor necrosis factor production GO:0032760 9.84 TLR3 TLR2 IFNG
9 B cell differentiation GO:0030183 9.83 IL10 IFNA2 IFNA1
10 positive regulation of inflammatory response GO:0050729 9.83 TLR3 TLR2 IL2 IFNG
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 IL2 IFNG IFNA2
12 positive regulation of interferon-gamma production GO:0032729 9.8 TLR3 IL2 HLA-A
13 interferon-gamma-mediated signaling pathway GO:0060333 9.8 IFNG HLA-DRB1 HLA-B HLA-A
14 positive regulation of cytokine production GO:0001819 9.79 TLR3 IL10 IFNG
15 type I interferon signaling pathway GO:0060337 9.78 IFNA2 IFNA1 HLA-B HLA-A
16 positive regulation of interleukin-12 production GO:0032735 9.77 TLR3 TLR2 IFNG
17 positive regulation of chemokine production GO:0032722 9.76 TLR3 TLR2 IFNG
18 response to exogenous dsRNA GO:0043330 9.75 TLR3 IFNA2 IFNA1
19 B cell proliferation GO:0042100 9.74 IL10 IFNA2 IFNA1
20 humoral immune response GO:0006959 9.73 PDCD1 IFNG IFNA2 IFNA1
21 regulation of immune response GO:0050776 9.73 PDCD1 HLA-B HLA-A FCGR3A COL17A1 CD8A
22 positive regulation of T cell mediated cytotoxicity GO:0001916 9.71 HLA-DRB1 HLA-B HLA-A
23 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.69 IFNG IFNA2 IFNA1
24 positive regulation of signaling receptor activity GO:2000273 9.67 IL10 IFNG
25 I-kappaB phosphorylation GO:0007252 9.66 TLR3 TLR2
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL10 IFNG
27 response to molecule of bacterial origin GO:0002237 9.65 TLR2 IL10
28 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.64 HLA-B HLA-A
29 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.64 HLA-B HLA-A
30 detection of bacterium GO:0016045 9.63 HLA-DRB1 HLA-B HLA-A
31 antigen processing and presentation GO:0019882 9.62 HLA-DRB1 HLA-B HLA-A CD8A
32 protection from natural killer cell mediated cytotoxicity GO:0042270 9.61 HLA-B HLA-A
33 adaptive immune response GO:0002250 9.61 PDCD1 IL2 IFNG IFNA2 IFNA1 HLA-DRB1
34 positive regulation of toll-like receptor signaling pathway GO:0034123 9.6 TLR3 TLR2
35 positive regulation of plasma cell differentiation GO:1900100 9.55 IL2 IL10
36 microglial cell activation GO:0001774 9.46 TRPV1 TLR3 TLR2 IFNG
37 immune response GO:0006955 9.36 TLR3 TLR2 IL2 IL10 IFNG HLA-DRB1

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.62 TRPV1 TLR3 TLR2 FCGR3A
2 peptide antigen binding GO:0042605 9.33 HLA-DRB1 HLA-B HLA-A
3 T cell receptor binding GO:0042608 9.26 HLA-DRB1 HLA-A
4 cytokine activity GO:0005125 9.02 IL2 IL10 IFNG IFNA2 IFNA1
5 TAP binding GO:0046977 8.96 HLA-B HLA-A
Sources

Sources for Herpes Zoster

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....